How "drug-like" are naturally occurring anti-cancer compounds?

Journal of Molecular Modeling

Volumn 20, Issue 1, 2014, Pages

  Ntie Kang, Fidele ^a,b   Lifongo, Lydia L ^a   Judson, Philip N ^c   Sippl, Wolfgang ^b   Efange, Simon M N ^a  

^a UNIVERSITY OF BUEA   (Cameroon)

^b MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^c Chemical and Bioactivity Information Centre   (United Kingdom)

Author keywords

Cancer; Drug metabolism; Drug likeness; In silico; Natural products; Pharmacokinetics; QSAR

Indexed keywords

ANTINEOPLASTIC AGENT; PLASMA PROTEIN;

ARTICLE; BIOAVAILABILITY; BIOLOGICAL MODEL; BLOOD BRAIN BARRIER; CHEMICAL DATABASE; CHEMISTRY; COMPARATIVE STUDY; COMPUTER SIMULATION; DRUG SCREENING; HUMAN; HYDROGEN BOND; MOLECULAR WEIGHT; PERMEABILITY; PROTEIN BINDING;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; BIOLOGICAL AVAILABILITY; BLOOD PROTEINS; BLOOD-BRAIN BARRIER; COMPUTER SIMULATION; DATABASES, CHEMICAL; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; HYDROGEN BONDING; MODELS, BIOLOGICAL; MOLECULAR WEIGHT; PERMEABILITY; PROTEIN BINDING;

EID: 84892574253     PISSN: 16102940     EISSN: 09485023     Source Type: Journal    
DOI: 10.1007/s00894-014-2069-z     Document Type: Article

References (70)

1. WHO media centre (2013) Cancer. Fact sheet N 297. http://www.who.int/ mediacentre/factsheets/fs297/en/index.html. Accessed on 28 August 2013
2. GLOBOCAN (2008) Gbobocan 2008. Fast Stats. http://globocan.iarc.fr/ factsheets/populations/factsheet.asp?uno=900. Accessed on 28 August 2013
3. Hartwell J (1970) Plants used against cancer. A survey. Lloydia 33:97-425
4. Ashidi JS, Houghton PJ, Hylands PJ, Efferth T (2010) Ethnobotanical survey and cytotoxicity testing of plants of South-western Nigeria used to treat cancer, with isolation of cytotoxic constituents from Cajanus cajan Millsp. leaves. J Ethnopharmacol 128:501-512
5. Graham JG, Quinn ML, Fabricant DS, Farnsworth NR (2010) Plants used against cancer - an extension of the work of Jonathan Hartwell. J Ethnopharmacol 73:347-377
6. Rahman MM, Khan MA (2013) Anti-cancer potential of South Asian plants. Nat Prod Bioprospect 3:74-88
7. Lamari FN, Cordopatis P (2008) Exploring the potential of natural products in cancer treatment. In: Missailidis S (ed) Anticancer therapeutics. Wiley-Blackwell, West Sussex
8. Cragg GM, Newman DJ (2003) Plants as a source of anti-cancer and anti-HIV agents. Ann Appl Biol 143:127-133
9. Pan L, Chai HB, Kinghorn AD (2013) Discovery of new anticancer agents from higher plants. Front Biosci (Schol Ed) 4:142-156
10. Wani MC, Taylor HL, Wall ME, Coggon P, McPhail AT (1971) Plant antitumor agents. VI. Isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J Am Chem Soc 93:2325-2327
11. Noble RH, Beer CT, Cutts JH (1959) Further biological activities of vincaleukoblastine - an alkaloid isolated from Vinca rosea (L.). Biochem Pharmacol 1:347-348
12. Neuss N, Gorman M, Boaz HE, Cone NJ (1962) Vinca alkaloids. XI. Structures of leurocristine and vincaleukoblastine. J Am Chem Soc 84:1509-1510
13. Svoboda GH (1961) Alkaloids of Vinca rosea (Catharanthus roseus). IX. Extraction and characterization of leurosidine and leurocristine. Lloydia 24:173-178
14. Hartwell JL, Schrecker AW (1951) Components of podophyllin. V. The constitution of podophyllotoxin. J Am Chem Soc 73:2909-2916
15. Wall ME, Wani MC, Cook CE, Palmer KH, McPhail AT, Sim GA (1966) Plant antitumor agents. I. The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from Camptotheca acuminata. J Am Chem Soc 88:3888-3890
16. Koehn FE, Carter GT (2005) The evolving role of natural products in drug discovery. Nat Rev Drug Discov 4:206-220
17. Newman DJ, Cragg GM (2012) Natural products as sources of new drugs over the 30 years from 1981 to 2010. J Nat Prod 75:311-335
18. Newman DJ, Cragg GM (2007) Natural products as sources of new drugs over the last 25 years. J Nat Prod 70:461-477
19. Harvey AL (2008) Natural products in drug discovery. Drug Discov Today 13:894-901
20. Lam KS (2007) New aspects of natural products in drug discovery. Trends Microbiol 15:279-289
21. Li JWH, Vederas JC (2009) Drug discovery and natural products: end of an era or an endless frontier? Science 325:161-165
22. Darvas F, Keseru G, Papp A, Dormán G, Urge L, Krajcsi P (2002) In silico and ex silico ADME approaches for drug discovery. Curr Top Med Chem 2:1287-1304
23. DiMasi JA, Hansen RW, Grabowsk HG (2003) The price of innovation: New estimates of drug development costs. J Health Econ 22:151-185
24. Cronin MTD (2003) Computer-assisted prediction of drug toxicity and metabolism in modern methods of drug discovery. In: Hilgenfeld R, Hillisch A (eds) Modern methods of drug discovery. Birkhäuser, Basel
25. Hodgson J (2001) ADMET - turning chemicals into drugs. Nat Biotechnol 19:722-726
26. Hansch C, Leo A, Mekapatia SB, Kurup A (2004) QSAR and ADME. Bioorg Med Chem 12:3391-3400
27. Tetko IV, Bruneau P, Mewes H-W, Rohrer DC, Poda GI (2006) Can we estimate the accuracy of ADMET predictions? Drug Discov Today 11:700-707
28. Greene N, Judson PN, Langowski JJ (1999) Knowledge-based expert systems for toxicity and metabolism prediction: DEREK, StAR and METEOR. SAR QSAR Environ Res 10:299-314
29. Button WG, Judson PN, Long A, Vessey JD (2003) Using absolute and relative reasoning in the prediction of the potential metabolism of xenobiotics. J Chem Inf Comput Sci 43:1371-1377
30. Ntie-Kang F, Mbah JA, Mbaze LM, Lifongo LL, Scharfe M, Ngo Hanna J, Cho-Ngwa F, Amoa Onguéné P, Owono Owono LC, Megnassan E, Sippl W, Efange SMN (2013) CamMedNP: building the Cameroonian 3D structural natural products database for virtual screening. BMC Complement Altern Med 13:88
31. Ntie-Kang F (2013) An in silico evaluation of the ADMET profile of the streptome DB database. Springer Plus 2:353
32. Ntie-Kang F, Lifongo LL, Mbah JA, Owono Owono LC, Megnassan E, Mbaze LM, Judson PN, Sippl W, Efange SMN (2013) In silico drug metabolism and pharmacokinetic profiles of natural products from medicinal plants in the Congo basin. In Silico Pharmacol 1:12
33. Ntie-Kang F, Mbah JA, Lifongo LL, Owono Owono LC, Megnassan E, Mbaze LM, Judson PN, Sippl W, Efange SMN (2013) Assessing the pharmacokinetic profile of the CamMedNP natural products database: An in silico approach. Org Med Chem Lett 3:10
34. Ntie-Kang F, Zofou D, Babiaka SB, Meudom R, Scharfe M, Lifongo LL, Mbah JA, Mbaze LM, Sippl W, Efange SMN (2013) AfroDb: A select highly potent and diverse natural product library from African medicinal plants. PLoS ONE 8(10): e78085. doi:10.1371/journal.pone.0078085
35. Mangal M, Sagar P, Singh H, Raghava GPS, Agarwal SM (2013) NPACT: Naturally occurring plant-based anti-cancer compound-activity-target database. Nucl Acids Res 41:D1124-D1129
36. Schrödinger (2011) LigPrep software, version 2.5. LLC, New York
37. Schrödinger (2011) Maestro, version 9.2. LLC, New York
38. Shivakumar D, Williams J, Wu Y, Damm W, Shelley J, Sherman W (2010) Prediction of absolute solvation free energies using molecular dynamics free energy perturbation and the OPLS force field. J Chem Theory Comput 6:1509-1519
39. Jorgensen WL, Maxwell DS, Tirado-Rives J (1996) Development and testing of the OPLS all-atom force field on conformational energetics and properties of organic liquids. J Am Chem Soc 118(45):11225-11236
40. Jorgensen WL, Tirado-Rives J (1988) The OPLS [optimized potentials for liquid simulations] potential functions for proteins, energy minimizations for crystals of cyclic peptides and crambin. J Am Chem Soc 110(6):1657-1666
41. Schrödinger (2011) QikProp, version 3.4. LLC, New York
42. Jorgensen WL, Duffy EM (2000) Prediction of drug solubility from Monte Carlo simulations. Bioorg Med Chem Lett 10:1155-1158
43. Jorgensen WL, Duffy EM (2002) Prediction of drug solubility from structure. Adv Drug Deliv Rev 54:355-366
44. Duffy EM, Jorgensen WL (2000) Prediction of properties from simulations: free energies of solvation in hexadecane, octanol, and water. J Am Chem Soc 122:2878-2888
45. Schrödinger Press (2011) QikProp 3.4 user manual. LLC, New York
46. Colmenarejo G, Alvarez-Pedraglio A, Lavandera J-L (2001) Cheminformatic models to predict binding affinities to human serum albumin. J Med Chem 44:4370-4378
47. Luco JM (1999) Prediction of brain-blood distribution of a large set of drugs from structurally derived descriptors using partial least squares (PLS) modelling. J Chem Inf Comput Sci 39:396-404
48. Kelder J, Grootenhuis PD, Bayada DM, Delbresine LP, Ploemen JP (1999) Polar molecular surface as a dominating determinant for oral absorption and brain pernetration of drugs. Pharm Res 16:1514-1519
49. Ajay, Bermis GW, Murkco MA (1999) Designing libraries with CNS activity. J Med Chem 42:4942-4951
50. Yazdanian M, Glynn SL, Wright JL, Hawi A (1998) Correlating partitioning and caco-2 cell permeability of structurally diverse small molecular weight compounds. Pharm Res 15:1490-1494
51. Irvine JD, Takahashi L, Lockhart K, Cheong J, Tolan JW, Selick HE, Grove JR (1999) MDCK (Madin-Darby canine kidney) cells: A tool for membrane permeability screening. J Pharm Sci 88:28-33
52. Stenberg P, Norinder U, Luthman K, Artursson P (2001) Experimental and computational screening models for the prediction of intestinal drug absorption. J Med Chem 44:1927-1937
53. + channel blockers. J Med Chem 45:3844-3853
54. De Ponti F, Poluzzi E, Montanaro N (2001) Organising evidence on QT prolongation and occurrence of Torsades de Pointes with non-antiarrhythmic drugs: A call for consensus. Eur J Clin Pharmacol 57:185-209
55. Potts RO, Guy RH (1992) Predicting skin permeability. Pharm Res 9:663-669
56. Potts RO, Guy RH (1995) A predictive algorithm for skin permeability: The effects of molecular size and hydrogen bond activity. Pharm Res 12:1628-1633
57. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ (1997) Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 23:3-25
58. Teague SJ, Davis AM, Leeson PD, Opea TI (1999) The design of leadlike combinatorial libraries. Angew Chem Int Ed 38:3743-3748
59. Oprea TI (2002) Current trends in lead discovery: Are we looking for the appropriate properties? J Comput Aided Mol Des 16:325-334
60. Schneider G (2002) Trends in virtual computational library design. Curr Med Chem 9:2095-2102
61. Verdonk ML, Cole JC, Hartshorn ML, Murray CW, Taylor RD (2003) Improved protein-ligand docking using GOLD. Proteins 52:609-623
62. Lipinski CA (2000) Drug-like properties and the causes of poor solubility and poor permeability. J Pharmacol Toxicol Methods 44:235-249
63. Quinn RJ, Carroll AR, Pham MB, Baron P, Palframan ME, Suraweera L, Pierens GK, Muresan S (2008) Developing a drug-like natural product library. J Nat Prod 71:464-468
64. Veber DF, Johnson SR, Cheng HY, Smith BR, Ward KW, Kopple KD (2002) Molecular properties that influence the oral bioavailability of drug candidates. J Med Chem 45:2615-2623
65. - (2005) Dictionary of natural products on CD-rom. Chapman and Hall/CRC Press, London
66. Hedley PL, Jørgensen P, Schlamowitz S, Wangari R, Moolman-Smook J, Brink PA, Kanters JK, Corfield VA, Christiansen M (2009) The genetic basis of long QT and short QT syndromes: A mutation update. Hum Mutat 30:1486-1511
67. + channels: friend or foe. Trends Pharmacol Sci 22:240-246
68. + channels: Spike-frequency adaptation. J Physiol 501:313-318
69. Aronov AM (2005) Predictive in silico modeling for hERG channel blockers. Drug Discov Today 10:149-155
70. Dunkel M, Fullbeck M, Neumann S, Preissner R (2006) Super natural: A searchable database of available natural compounds. Nucl Acids Res 34:D678-D683